Compare CAKE & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAKE | DNLI |
|---|---|---|
| Founded | 1972 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.0B |
| IPO Year | 1996 | 2017 |
| Metric | CAKE | DNLI |
|---|---|---|
| Price | $66.58 | $21.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 14 |
| Target Price | ★ $60.31 | $34.33 |
| AVG Volume (30 Days) | 1.1M | ★ 1.8M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.92% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.02 | N/A |
| Revenue | ★ $3,751,806,000.00 | N/A |
| Revenue This Year | $6.14 | N/A |
| Revenue Next Year | $6.65 | $408.85 |
| P/E Ratio | $63.24 | ★ N/A |
| Revenue Growth | ★ 4.75 | N/A |
| 52 Week Low | $43.07 | $12.58 |
| 52 Week High | $69.70 | $23.77 |
| Indicator | CAKE | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 65.96 | 61.34 |
| Support Level | $56.82 | $17.99 |
| Resistance Level | $66.50 | $22.07 |
| Average True Range (ATR) | 2.22 | 0.90 |
| MACD | 0.65 | 0.25 |
| Stochastic Oscillator | 93.99 | 96.25 |
The Cheesecake Factory Inc is a restaurant company that owns and operates multiple casual dining brands across the United States and Canada under brands that include The Cheesecake Factory, North Italia, Flower Child, and additional brands within its Fox Restaurant Concepts portfolio. The company's international presence, in the Middle East and Mexico, is through licensing agreements with third parties. The company also has a bakery division that produces cheesecakes and other baked products for sale in its restaurants, international licensees, and third-party bakery customers. The company has four operating business segments: The Cheesecake Factory restaurants, North Italia, Other FRC, and Other. The majority of the company's revenue comes from the Cheesecake Factory restaurants segment.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.